{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:28:03Z","timestamp":1760711283827,"version":"3.43.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.acuroe.2023.12.001","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T11:57:45Z","timestamp":1702468665000},"page":"410-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical evaluation and treatment in men with low testosterone levels and prostate cancer"],"prefix":"10.1016","volume":"48","author":[{"given":"B.M.","family":"Ljubetic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Parada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuroe.2023.12.001_bib0005","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","article-title":"Evaluation and management of testosterone deficiency: AUA guideline","volume":"200","author":"Mulhall","year":"2018","journal-title":"J Urology"},{"key":"10.1016\/j.acuroe.2023.12.001_bib0010","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bju.14899","article-title":"Guideline of guidelines: testosterone therapy for testosterone deficiency","volume":"124","author":"Salter","year":"2019","journal-title":"Bju Int"},{"key":"10.1016\/j.acuroe.2023.12.001_bib0015","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.eururo.2021.06.007","article-title":"European association of urology guidelines on sexual and reproductive health-2021 update: male sexual dysfunction","volume":"80","author":"Salonia","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2023.12.001_bib0020","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.eururo.2015.12.005","article-title":"Testosterone therapy in men with prostate cancer","volume":"69","author":"Kaplan","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2023.12.001_bib0025","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jsxm.2019.03.262","article-title":"Testosterone deficiency: a review and comparison of current guidelines","volume":"16","author":"Kwong","year":"2019","journal-title":"J Sex Med"},{"key":"10.1016\/j.acuroe.2023.12.001_bib0030","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.ijir.3901397","article-title":"Male hypogonadism. Part I: Epidemiology of hypogonadism","volume":"18","author":"Seftel","year":"2006","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.acuroe.2023.12.001_bib0035","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/aja.2011.106","article-title":"Impact of androgen deprivation therapy on sexual function","volume":"14","author":"Mazzola","year":"2012","journal-title":"Asian J Androl"},{"key":"10.1016\/j.acuroe.2023.12.001_bib0040","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa1206168","article-title":"Gonadal steroids and body composition, strength, and sexual function in men","volume":"369","author":"Finkelstein","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuroe.2023.12.001_bib0045","doi-asserted-by":"crossref","first-page":"18424","DOI":"10.18632\/oncotarget.12906","article-title":"Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance","volume":"8","author":"Ferro","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.acuroe.2023.12.001_bib0050","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/bju.13206","article-title":"Low testosterone level is an independent risk factor for high-grade prostate cancer detection at biopsy","volume":"118","author":"Park","year":"2016","journal-title":"Bju Int"},{"key":"10.1016\/j.acuroe.2023.12.001_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsxm.2022.01.003","article-title":"The relationship between PSA and total testosterone levels in men with prostate cancer","author":"Flores","year":"2022","journal-title":"J Sex Med"},{"key":"10.1016\/j.acuroe.2023.12.001_bib0060","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00345-011-0793-x","article-title":"Low serum testosterone levels are predictive of prostate cancer","volume":"31","author":"Mearini","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.acuroe.2023.12.001_bib0065","doi-asserted-by":"crossref","first-page":"921","DOI":"10.21037\/tau.2016.09.08","article-title":"Impact of recent FDA ruling on testosterone replacement therapy (TRT)","volume":"5","author":"Metzger","year":"2016","journal-title":"Transl Androl Urol"},{"year":"2023","series-title":"European Medicines Agency PRAC European Medicines Agency","author":"Agency","key":"10.1016\/j.acuroe.2023.12.001_bib0070"},{"key":"10.1016\/j.acuroe.2023.12.001_bib0075","first-page":"970","article-title":"European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: Endorsing organization","volume":"8","author":"Corona","year":"2020","journal-title":"European Society of Endocrinology, Andrology"},{"key":"10.1016\/j.acuroe.2023.12.001_bib0080","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jsxm.2022.03.619","article-title":"The pre-testosterone therapy checklist","volume":"19","author":"Flores","year":"2022","journal-title":"J Sex Med"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578623001373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578623001373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T07:41:31Z","timestamp":1754984491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578623001373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2173578623001373"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2023.12.001","relation":{},"ISSN":["2173-5786"],"issn-type":[{"type":"print","value":"2173-5786"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical evaluation and treatment in men with low testosterone levels and prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2023.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2023.09.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}